Oncology · NSCLC
Time to confirmed diagnosis
The Patient Journey isolated a referral barrier between pulmonology and oncology. Redesigning the message to first-contact physicians shortened the patient route.
Patient Journey
Pharmaceutical market research · Mexico and LATAM
We design the study, run fieldwork on our own physician panel and model the result until it answers your business question.







Chapter I
Without a declared method, a finding is an expensive opinion.
Data quality starts with who answers. Every filter in the figure is a real panel control.
We recruit and validate every physician: professional license, specialty, institution and real consultation volume. No one joins the panel without documentary verification.
That enables something a rented panel cannot: reaching exactly the same cohort wave after wave and reading the change instead of the noise.
Typical field time: 3–6 weeks · active practice reviewed every semester
How the panel is builtDeclared method, declared sample, findings with the decision attached. Every study ships with its protocol: what was asked, of whom, how the sample was selected and the margin of error each figure carries.
We translate the business question into measurable hypotheses and define universe, sampling frame, inclusion criteria and statistical power. The protocol is signed before recruitment starts.
Recruitment from our own panel with professional license and active practice verification. Double quality control: validation at capture and audit of 20% of interviews. We also field on the client's own panel, according to the needs and definitions of the study.
Weighting to the physician universe, declared significance testing and 95% confidence intervals. Every table travels with its base and its error level.
The report closes with the action: what to do, in what priority, what gets re-measured and when. Working session with your team included.
Standards we apply
They are chosen by the decision in front of you, not from a catalogue. They almost always combine: one maps the terrain, another keeps it measured over time.
Who we answer to
The physician receives five competing messages a week and the patient rarely arrives adherent. That is where your share is decided, and that is where we measure.
IMSS, ISSSTE, IMSS-Bienestar and PEMEX do not buy without evidence of economic value. We build the quantitative argument that withstands review.
There is a gap between trial evidence and Mexican clinical practice. We measure it: real-world use, referral patterns and guideline adherence.
Each page declares minimum sample, field timing, deliverable and the function it answers to.

Epidemiology, Usage & Attitudes, Brand Tracker and dynamic forecasting in a single living model, recalibrated every quarter against real prescription. Interactive dashboard included.

The full patient route, from symptom to 12-month adherence: diagnostic barriers, intervention windows and the points where the clinical decision is actually made.

Real prescribing habit measured on a verified panel: choice drivers, switching barriers and perceived efficacy and safety against the competitive set.

Positioning measured wave after wave on a fixed panel: Top of Mind, share of prescription, NPS and brand equity, with a read on competitive movement.

Eligible-patient sizing by indication using ENSANUT, IMSS, Ministry of Health data and systematic review. Diagnosis-to-treatment funnel by biomarker, sector and institution.

Cost-effectiveness, cost-utility (QALY / ICER) and budget impact built to ISPOR standards, designed to withstand payer review.

Message recall, copy testing, KOL mapping, advisory boards and real-world evidence. If the question does not fit a format, we design an ad hoc study from scratch.
Projects anonymised under confidentiality agreement. We publish the challenge, the methodology and the decision the study enabled; quantitative results remain the client's property.
15 years of team experience with global Top 10 pharmaceutical companies · results under NDA
Oncology · NSCLC
The Patient Journey isolated a referral barrier between pulmonology and oncology. Redesigning the message to first-contact physicians shortened the patient route.
Patient Journey
Diabetes · GLP-1
Four Brand Tracker waves caught the competitor's narrative shift a quarter before the planning cycle. The brand reacted in time.
Brand Tracker
Biologic · Access
The pharmacoeconomic dossier withstood review and secured inclusion in the first evaluation cycle, with no round of clarifications.
Pharmacoeconomics / HEOR · ISPOR standard
In under 48 business hours you receive scope, methodology, proposed sample, field timing and investment range. No cost, no commitment. Request a proposal
hola@scopusconsulting.com.mx · +52 442 388 5410
Mon–Fri · 9:00–19:00 CT